#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





(10) International Publication Number WO 2013/124385 A3

(43) International Publication Date 29 August 2013 (29.08.2013)

(51) International Patent Classification: *C07D 401/12* (2006.01)

(21) International Application Number:

PCT/EP2013/053499

(22) International Filing Date:

21 February 2013 (21.02.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12382065.6 23 February 2012 (23.02.2012) EP 61/607,741 7 March 2012 (07.03.2012) US

- (71) Applicant: ESTEVE QUÍMICA, S.A. [ES/ES]; Av. Mare de Déu de Montserrat, 12, E-08024 Barcelona (ES).
- (72) Inventors: BARTRA SANMARTÍ, Martí; C.Entença, 100, 2º 3ª, E-08015 Barcelona (ES). ESPINOSA FERRER, Rosa Maria; C/ Doctor Moragas, 235, 3º 3ª, E-08210 Barberà Del Vallès (ES). LUPON ROSES, Maria del Pilar; C. Mandri, 54, E-08022 Barcelona (ES). WINTER, Stephen Benedict David; Bonavista, 10, E-08690 Santa Coloma De Cervelló (ES). DONNICI GARCIA, Silvia; Av Mistral, 36 4º 3ª esc derecha, E-08015 Barcelona (ES).
- (74) Agent: ZBM PATENTS- ZEA, BARLOCCI & MARK-VARDSEN; Pl. Catalunya, 1, E-08002 Barcelona (ES).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

 as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

#### Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- (88) Date of publication of the international search report:

5 December 2013



International application No. PCT/EP2013/053499

# **INTERNATIONAL SEARCH REPORT**

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  1-6
The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.  The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.  No protest accompanied the payment of additional search fees.

# **INTERNATIONAL SEARCH REPORT**

International application No PCT/EP2013/053499

	FICATION OF SUBJECT MATTER C07D401/12		
According to	n International Patent Classification (IPC) or to both national classifica	tion and IPC	
	SEARCHED		
CO7D	cumentation searched (classification system followed by classificatio	n symbols)	
Documenta	tion searched other than minimum documentation to the extent that su	uch documents are included in the fields sea	arched
Electronic d	ata base consulted during the international search (name of data bas	se and, where practicable, search terms use	ed)
EPO-In	ternal, CHEM ABS Data, WPI Data		
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.
Х	DE 10 2005 061623 A1 (BOEHRINGER PHARMA [DE]) 28 June 2007 (2007-0 Scheme II, Examples 5-8		1-6
А	WO 2005/028468 A1 (BOEHRINGER ING INT [DE]; BOEHRINGER INGELHEIM PH [DE]; SOBOT) 31 March 2005 (2005- cited in the application the whole document	HARMA	1-6
A	WO 2011/110876 A1 (EGIS GYOGYSZER NYILVANOSAN MUKOEDO RESZVENYTARS/KIRALY I) 15 September 2011 (2017 cited in the application page 17, paragraph 3 - page 18, example 15	ASAG [HU]; 1-09-15)	1-6
Furti	ner documents are listed in the continuation of Box C.	X See patent family annex.	
* Special c	ategories of cited documents : ent defining the general state of the art which is not considered	"T" later document published after the inter date and not in conflict with the applic the principle or theory underlying the i	ation but cited to understand
"E" earlier a	of particular relevance Application or patent but published on or after the international	"X" document of particular relevance; the c	
filing d "L" docume	ate ent which may throw doubts on priority claim(s) or which is	considered novel or cannot be considered step when the document is taken alon	ered to involve an inventive
cited to specia	o establish the publication date of another citation or other Il reason (as specified) ent referring to an oral disclosure, use, exhibition or other	"Y" document of particular relevance; the c considered to involve an inventive ste combined with one or more other such	p when the document is
means	; ent published prior to the international filing date but later than	being obvious to a person skilled in th	e art
<u>`</u>	ority date claimed actual completion of the international search	"&" document member of the same patent  Date of mailing of the international sea	<u> </u>
2	2 May 2013	16/10/2013	
Name and r	nailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Mooren, Nicolai	

### INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2013/053499

D. C.	D. J. P P.		D. Hantag
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 102005061623 A1	28-06-2007	AR 058570 A AU 2006326979 A BR P10620204 A CA 2631832 A CN 101346360 A DE 102005061623 A EP 1966171 A JP 2009520765 A KR 20080077029 A NZ 569851 A TW 200804302 A US 2007185333 A US 2010210845 A WO 2007071742 A ZA 200804030 A	28-06-2007 A2 01-11-2011 A1 28-06-2007 A1 14-01-2009 A1 28-06-2007 A1 10-09-2008 A 28-05-2009 A 20-08-2008 A 28-10-2011 A 16-01-2008 A 09-08-2007 A1 19-08-2010 A1 28-06-2007
WO 2005028468 A1	31-03-2005	AR 045520 A AR 073225 A AT 430145 T AT 529420 T AU 2004274139 A AU 2010201457 A BR P10413849 A CA 2537054 A CA 2749579 A CN 1845917 A CN 102167695 A CO 5660265 A DE 10339862 A DK 1660482 T DK 2060569 T EC SP066399 A EC SP11006399 A EC SP11006399 A EP 1660482 A EP 2060569 A ES 2326654 T ES 2375896 T HK 1096682 A HR P20120028 T HK 1096682 A HR P20120028 T JP 2007504106 A JP 2011178803 A ME P50608 A MX PA06001959 A MY 145632 A MY 145632 A MY 145696 A MX PA06001959 A MY 145632 A MY 145696 A MX PA06001959 A MY 145632 A MY 145696 A MX PA06001959 A MY 145632 A MY 145696 A MX PA06001959 A MY 145632 A MY 145696 A MX PA06001959 A MY 145632 A MY 145696 A MX PA06001959 A MY 145632 A MY 145696 A MX PA06001959 A MY 145696 A MY	20-10-2010 15-05-2009 15-11-2011 31-03-2005 31 06-05-2010 24-10-2006 31-03-2005 31-03-2005 31-07-2006 31-08-2011 32-01-2012 31-07-2006 31-08-2011 31-05-2006 31-05-2009 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2011 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012 31-01-2012

### INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2013/053499

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
	•	US UY UY WO	2008119523 A1 28493 A1 32342 A 2005028468 A1	22-05-2008 31-03-2005 29-07-2011 31-03-2005
WO 2011110876 A	15-09-2011	CN EA WO	102858762 A 201290726 A1 2011110876 A1	02-01-2013 30-07-2013 15-09-2011

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6

A crystalline Form A of dabigatran etexilate mesylate characterized by having an X-ray diffractogram with characteristic peaks as indicated in claim 1; a pharmaceutical composition thereof; processes for its preparation

2. claims: 7-12

An amorphous form of dabigatran etexilate mesylate, a pharmaceutical composition thereof; processes for its preparation

3. claims: 13, 14

A crystalline Form A of dabigatran etexilate base characterized by having an X-ray diffractogram with characteristic peaks as indicated in claim 13; a process for its preparation

---